Dual targeting of the androgen receptor and PI3K/AKT/mTOR pathways in prostate cancer models improves antitumor efficacy and promotes cell apoptosis.
Sugawara T, Nevedomskaya E, Heller S, Böhme A, Lesche R, von Ahsen O, Grünewald S, Nguyen HM, Corey E, Baumgart SJ, Georgi V, Pütter V, Fernández-Montalván A, Vasta JD, Robers MB, Politz O, Mumberg D, Haendler B.
Sugawara T, et al. Among authors: bohme a.
Mol Oncol. 2024 Mar;18(3):726-742. doi: 10.1002/1878-0261.13577. Epub 2024 Jan 15.
Mol Oncol. 2024.
PMID: 38225213
Free PMC article.